ArticlePloS one2026
Real world experience with cyclin dependent kinase inhibitors in metastatic breast cancer in India.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe present study evaluated the real-world experience with cyclin dependent kinase 4/6 inhibitors palbociclib and ribociclib in hormone receptor-positive/ human epidermal growth factor receptor 2-negative (HR + /HER2-) metastatic breast cancer.
methodThis study was conducted on the HR + /HER2- metastatic breast cancer patients who received palbociclib/ ribociclib in the first line or recurrent setting between January 2021 and January 2023 along with endocrine therapy. Data was retrieved from the Hospital medical records.
resultsIn the patients receiving palbociclib, a better median progression free survival (PFS) was observed in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 (27.3 months,p-value <0.0001), de novo disease (17.5 months,p-value 0.0155), first line hormonal therapy (22.5 months,p-value <0.0001) and no prior chemotherapy (20.3 months,p-value 0.0001). Similarly, in the patients receiving ribociclib, a better median PFS was observed in patients with ECOG PS 1 (22.2 months,p-value <0.0001), de novo disease (21.7 months,p-value 0.0042), first-line hormonal therapy (22.5 months,p-value <0.0001) and no prior chemotherapy (21.7 months,p-value <0.0001). On multivariate analysis, ECOG PS, line of hormone therapy and prior chemotherapy showed significance (p-values <0.0001, < 0.0001 & 0.0269, respectively).
conclusionThe study shows real-world experience with cyclin dependent kinase 4/6 inhibitors palbociclib and ribociclib in metastatic breast cancer in India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.